Aprea Therapeutics, Inc. (APRE): Operating Cash Flow
-$12.89M
Year ended 2025-12-31
-$12.17M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$12.89M | n/m | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | -$13.56M | n/m | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | -$12.18M | n/m | 2025-03-25, From 2023-01-01 |
| 2022-12-31 | -$25.01M | n/m | 2024-03-26, From 2022-01-01 |
| 2021-12-31 | -$37.69M | n/m | 2024-03-26, From 2021-01-01 |
| 2020-12-31 | -$41.80M | n/m | 2023-03-30, From 2020-01-01 |
| 2019-12-31 | -$26.71M | n/m | 2022-03-15, From 2019-01-01 |
| 2018-12-31 | -$15.25M | n/m | 2021-03-16, From 2018-01-01 |
| 2017-12-31 | -$14.00M | n/a | 2020-03-27, From 2017-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Aprea Therapeutics, Inc. (APRE) | 2025-12-31 | -$12.89M | n/m |
| Reviva Pharmaceuticals Holdings, Inc. (RVPH) | 2025-12-31 | -$24.59M | n/m |
| Anixa Biosciences Inc (ANIX) | 2025-10-31 | -$7.17M | n/m |
| Synlogic, Inc. (SYBX) | 2025-12-31 | -$4.36M | n/m |
| Aditxt, Inc. (ADTX) | 2025-12-31 | -$25.69M | n/m |
| Cingulate Inc. (CING) | 2025-12-31 | -$17.25M | n/m |
| Tempest Therapeutics, Inc. (TPST) | 2025-12-31 | -$26.82M | n/m |
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | -$23.12M | n/m |
| Lipocine Inc. (LPCN) | 2025-12-31 | -$9.76M | n/m |
Compare APRE, RVPH, ANIX, SYBX side by side · Screen every company in Pharmaceutical Preparations ↗